Status:
UNKNOWN
Ruxolitinib Combined With Dexamethasone for HLH
Lead Sponsor:
Capital Research Institute of Pediatrics
Conditions:
Hemophagocytic Lymphohistiocytosis
Eligibility:
All Genders
1-18 years
Phase:
PHASE1
PHASE2
Brief Summary
A protocol named as "HLH-DR" for patients with refractory and secondary hemophagocytic lymphohistiocytosismay.
Detailed Description
A modified protocol about ruxolitinib combined with dexamethasone which includes oral ruxolitinib (2.5 mg twice daily for patients if the age\<14 years and the weight \<25kg，5 mg twice daily for patie...
Eligibility Criteria
Inclusion
- Secondary and refractory HLH.
Exclusion
- Family HLH.
Key Trial Info
Start Date :
March 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2022
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT03795909
Start Date
March 1 2017
End Date
March 1 2022
Last Update
January 8 2019
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Yan Yue
Beijing, Chaoyang District, China, 100020
2
Yan Yue
Beijing, China